Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Sage Therapeutics Announces Discontinuation of Collaboration with Biogen on SAGE-324 Program
Sep 26, 2024•almost 2 years ago
Contract Type
partnership
CambridgeBiotechnologyHealth CareTherapeutics
Description
Sage Therapeutics, Inc. has announced the termination of its collaboration and license agreement with Biogen specific to the SAGE-324 program. Despite this discontinuation, both companies will continue to partner on ZURZUVAE (zuranolone) for the treatment of postpartum depression (PPD), aiming to support women suffering from PPD.
Company Information
Company
Sage Therapeutics
Location
Cambridge, Massachusetts, United States
About
Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.
Predictive Intelligence
Strategic
ML-powered predictions for Sage Therapeutics's next move